Cancer procoagulant as a marker in monitoring the therapy in cases of oesophageal, stomach and colorectal cancer.
Cancer procoagulant activity in the blood serum of patients with oesophagal, gastric and colorectal cancer was evaluated before and after the tumour removal. Cancer procoagulant activity was significantly higher before the operation in comparison to the control group and was reduced after a total operative procedure, whereas it was kept on a high level after a non-radical procedure or in cases of metastases. Examination results point to the possibility of using the evaluation of cancer procoagulant activity in monitoring the course of treatment of patients with oesophagal, gastric and colorectal cancer.
Kozuszko
B
B
Department of Clinical Analysis, Medical Academy, Białystok, Poland.
Skrzydlewska
E
E
Snarska
J
J
Kozłowski
M
M
Zalewski
B
B
Skrzydlewski
Z
Z
D015415:Biomarkers; D015179:Colorectal Neoplasms / Q000097:blood / Q000628:therapy; D003546:Cysteine Endopeptidases / Q000097:blood*; D004938:Esophageal Neoplasms / Q000097:blood / Q000628:therapy; D005770:Gastrointestinal Neoplasms / Q000097:blood* / Q000628:therapy; D006801:Humans; D009363:Neoplasm Proteins; D011237:Predictive Value of Tests; D012680:Sensitivity and Specificity; D013274:Stomach Neoplasms / Q000097:blood / Q000628:therapy
D015415:Biomarkers; D009363:Neoplasm Proteins; D003546:Cysteine Endopeptidases; C030910:cancer procoagulant